Please ensure Javascript is enabled for purposes of website accessibility

Pacific Biosciences of California Pushing Toward Sustainable Growth

By Travis Hoium - Apr 22, 2016 at 9:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new product will help Pacific Biosciences of California realize some of the potential in its DNA.

First-quarter 2016 earnings from gene sequencer Pacific Biosciences of California (PACB -6.10%) were released after the market closed on Thursday, and the company's transition to sustainable long-term viability continued. The company launched the Sequel System late in 2015, and there's a slow rollout of systems this year as management works out bugs.

If early results are any indication, however, investors should start to see consistent growth and a move toward profitability in the future. 

Pacific Biosciences of California results: The raw numbers

 

Q1 2016 Actuals

Q1 2015 Actuals

Growth (YOY)

Sales

$19.1 million

$17.6 million

8%

Net income

($19.4 million)

($20.2 million)

n/a

Adjusted earnings per share

($0.23)

($0.27)

n/a

Data source: Company earnings report.

What happened with Pacific Biosciences of California this quarter?
The general theme of the quarter was that the Sequel System launch is going as planned, and management is actually fulfilling orders more slowly than it could to make sure there aren't any bugs when customers start working with the product. But you can start to see the financial improvements, and other metrics start to pick up, as well. Here are a few highlights.

  • Gross profit increased from $5.9 million a year ago, or 33.6% of sales, to $9.5 million, or 49.7% of sales. The increase was due to higher-margin sales of Sequel Systems.
  • Thirty Sequel Systems were ordered in the quarter, half from new customers. Eighteen systems shipped versus 10 in Q4 2015. Going forward, Sequel will be almost all of the company's shipments.
  • In total, there have been 79 Sequel System orders in two quarters, which is about half of the number of systems the last generation sold in five years.
  • Despite the continued losses, the company has a lot of runway, with $91.5 million on the balance sheet.

The Sequel System. Image source: Pacific Biosciences.

What management had to say
Management was still very bullish on the long-term trajectory of the company on its conference call. They said revenue for the year will be at least $93 million, with a gross margin in the high 40% range. Net loss will be about $73 million, partly due to the end of Roche contract revenue that the company has benefited from in the past. For this upcoming quarter, management expects to grow sequentially as more systems ship to customers and product revenue picks up.

This summer, there will be a transition to a high-volume smart-cell supplier, which should bring higher margins. Along with software updates, this will help drive higher shipments of Sequel in the second half of the year.

Looking forward
Clearly, losses will continue for Pacific Biosciences, but the new Sequel System appears to be performing well and is starting to improve financial statements. Long term, that should help drive the company toward profitability, with ongoing product revenue from cells. As 2016 unfolds, growth in installs, backlog, and cell revenue is what investors will need to keep an eye on as signs the business is on the right path.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$5.39 (-6.10%) $0.35

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.